Bredell Marius, Rordorf Tamara, Kroiss Sabine, Rücker Martin, Zweifel Daniel Fritz, Rostetter Claudio
Private Practice and Visiting Consultant, Cantonal Hospital Winterthur, Winterthur, Switzerland.
Consultant, Department of Oncology, University Hospital of Zurich, Zurich, Switzerland.
J Oral Maxillofac Surg. 2018 Apr;76(4):775-784. doi: 10.1016/j.joms.2017.09.013. Epub 2017 Sep 21.
Giant cell granuloma (GCG) of the jaw is a rare disease with high morbidity. Various treatment options have been discussed in the past. Since 2010, a pharmaceutical therapy with denosumab seems to have been successful for giant cell tumors of the femur. The authors hypothesized the equally successful use of denosumab for GCGs of the jaws.
In the present retrospective cohort study, 5 patients with large GCGs of the jaws were treated with denosumab with a follow-up of 25 to 49 months. Frequent clinical follow-ups and a radiologic follow-up were performed and systematically analyzed.
All patients showed a curative treatment response and complete metabolic resolution of the GCGs under treatment with denosumab.
A brief review of the relevant literature and a detailed evaluation of current cases led to the conclusion that denosumab therapy should be considered a therapeutic option for large central GCGs of the jaws. The results of this study suggest denosumab is a successful treatment option. A treatment length no shorter than 12 months is recommended and monitoring of treatment response can be well managed by positron-emission tomographic computed tomography or magnetic resonance imaging.
颌骨巨细胞肉芽肿（GCG）是一种发病率较高的罕见疾病。过去已讨论过各种治疗方案。自2010年以来，地诺单抗药物治疗似乎已成功用于股骨巨细胞瘤。作者推测地诺单抗同样可成功用于颌骨GCG。
在本回顾性队列研究中，5例颌骨大型GCG患者接受了地诺单抗治疗，随访时间为25至49个月。进行了频繁的临床随访和放射学随访并进行系统分析。
所有患者在接受地诺单抗治疗后均显示出治愈性治疗反应，GCG完全代谢消退。
对相关文献的简要回顾和对当前病例的详细评估得出结论，地诺单抗治疗应被视为颌骨大型中央型GCG的一种治疗选择。本研究结果表明地诺单抗是一种成功的治疗选择。建议治疗时长不少于12个月，并且可以通过正电子发射断层扫描计算机断层扫描或磁共振成像很好地管理治疗反应监测。
